CELGENE CORP /DE/
CIK 816284 · last filed 2020-07-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUMMIT, NJ 07901
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACCELERON PHARMA INC (XLRN) Delisted | 10%+ Owner | 7,008,510 | $178.75 | $1.25B | $134.50M | 7 | 2020-07-13 |
| STRO | 10%+ Owner | 172,620 | $8.88 | $1.53M | $0 | 1 | 2018-10-02 |
| AGIO | 10%+ Owner | 6,718,433 | $36.85 | $247.57M | $618.13M | 4 | 2018-01-31 |
| CRISPR Therapeutics AG (PZRX) Delisted | 10%+ Owner | 8,727,849 | — | — | $1.29M | 3 | 2017-12-07 |
| Alliqua BioMedical, Inc. (ALQA) Delisted | 10%+ Owner | 1,223,730 | — | — | $5.00M | 3 | 2017-04-13 |
| GLOBEIMMUNE INC (GBIM) Delisted | 10%+ Owner | 669,502 | — | — | $4.00M | 1 | 2014-07-08 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 3,267,974 | $1.47 | $4.80M | $2.00M | 1 | 2013-06-06 |
Recent Filings · Page 2 of 2
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-03-01 | Alliqua BioMedical, Inc. (ALQA) Delisted | Buy (P) | +4,000,000 | $2.00M | EDGAR |
| 2016-10-27 | CRISPR Therapeutics AG (PZRX) Delisted | Mixed | +4,834,980 | $11.20M | EDGAR |
| 2016-10-26 | CRISPR Therapeutics AG (PZRX) Delisted | Mixed | +4,834,980 | $11.20M | EDGAR |
| 2016-01-11 | ACCELERON PHARMA INC (XLRN) Delisted | Buy (P) | +800,000 | $32.00M | EDGAR |
| 2015-05-04 | Alliqua BioMedical, Inc. (ALQA) Delisted | Buy (P) | +659,340 | $3.00M | EDGAR |
| 2014-07-08 | GLOBEIMMUNE INC (GBIM) Delisted | Mixed | +1,201,340 | $4.00M | EDGAR |
| 2014-01-29 | ACCELERON PHARMA INC (XLRN) Delisted | Buy (P) | +300,000 | $15.00M | EDGAR |
| 2013-09-26 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | +3,172,887 | $10.00M | EDGAR |
| 2013-07-30 | AGIO | Mixed | +14,157,777 | $38.25M | EDGAR |
| 2013-06-06 | Epizyme, Inc. (EPZM) Delisted | Mixed | +6,669,280 | $2.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.